413 related articles for article (PubMed ID: 35877260)
1. Emerging Biomarker-Guided Therapies in Prostate Cancer.
Deluce JE; Cardenas L; Lalani AK; Maleki Vareki S; Fernandes R
Curr Oncol; 2022 Jul; 29(7):5054-5076. PubMed ID: 35877260
[TBL] [Abstract][Full Text] [Related]
2. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
3. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy.
Ceci F; Airò Farulla LS; Bonatto E; Evangelista L; Aliprandi M; Cecchi LG; Mattana F; Bertocchi A; DE Vincenzo F; Perrino M; Cordua N; Borea F; Zucali PA
Q J Nucl Med Mol Imaging; 2024 Jun; 68(2):101-115. PubMed ID: 38860274
[TBL] [Abstract][Full Text] [Related]
4. Management of Advanced Prostate Cancer in the Precision Oncology Era.
Gillette CM; Yette GA; Cramer SD; Graham LS
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174018
[TBL] [Abstract][Full Text] [Related]
5. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
8. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
9. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
10. [Molecular tumor board prostate cancer].
Seitz AK; Heck MM; Kamer MW; Grüllich C
Urologe A; 2019 Jul; 58(7):752-759. PubMed ID: 31049637
[TBL] [Abstract][Full Text] [Related]
11. Treatment strategies for DNA repair-deficient prostate cancer.
Teply BA; Antonarakis ES
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):889-898. PubMed ID: 28573914
[TBL] [Abstract][Full Text] [Related]
12. Genetic Testing in Prostate Cancer.
Sokolova AO; Cheng HH
Curr Oncol Rep; 2020 Jan; 22(1):5. PubMed ID: 31974718
[TBL] [Abstract][Full Text] [Related]
13. Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology.
Batra A; Glick D; Valdes M
Curr Oncol; 2024 Feb; 31(2):1047-1062. PubMed ID: 38392072
[TBL] [Abstract][Full Text] [Related]
14. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
15. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
16. PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P; Schiewer MJ; Knudsen KE; Kelly WK
Curr Treat Options Oncol; 2017 Jun; 18(6):37. PubMed ID: 28540598
[TBL] [Abstract][Full Text] [Related]
17. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
18. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
19. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Xia M; Guo Z; Hu Z
Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Marshall CH; Antonarakis ES
Cancer Treat Res Commun; 2020 Jan; 23():100164. PubMed ID: 31978677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]